A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis.
Roni Tamari
(1)
,
Donal P. Mclornan
(2)
,
Kwang Woo Ahn
(3)
,
Noel Estrada-Merly
(3)
,
Juan Carlos Hernandez-Boluda
(4)
,
Sergio A. Giralt
(1)
,
Jeanne M. Palmer
(5)
,
Robert Peter Gale
(6)
,
Zachariah Defilipp
(7)
,
David I. Marks
(8)
,
Marjolein W. M. van der Poel
(9)
,
Leo F. Verdonck
,
Minoo Battiwalla
(10)
,
Miguel Angel Díaz
(11)
,
Vikas Gupta
(12)
,
Haris Ali
(13)
,
Mark Robert Litzow
(14)
,
Hillard M. Lazarus
(15)
,
Usama Gergis
(16)
,
Asad Bashey
(17)
,
Jane L. Liesveld
(18)
,
Shahrukh Hashmi
(14)
,
Jeffrey J. Pu
,
Amer Beitinjaneh
(19)
,
Christopher N. Bredeson
(20)
,
David A. Rizzieri
,
Bipin N. Savani
(21)
,
Muhammad Bilal Abid
(3)
,
Siddhartha Ganguly
(22)
,
Vaibhav Agrawal
(13)
,
Vera Ulrike Bacher
(23)
,
Baldeep Wirk
(24)
,
Tania Jain
(25)
,
Corey S. Cutler
(26)
,
Mahmoud Aljurf
(27)
,
Tamila Kindwall-Keller
(28)
,
Mohamed A. Kharfan-Dabaja
(29)
,
Gerhard C. Hildebrandt
(30)
,
Attaphol Pawarode
(31)
,
Melhem M. Solh
(17)
,
Jean A. Yared
(32)
,
Michael R. Grunwald
,
Sunita Nathan
(33)
,
Taiga Nishihori
(34)
,
Sachiko Seo
(35)
,
Bart L. Scott
(36)
,
Ryotaro Nakamura
(13)
,
Betul Oran
(37)
,
Tomasz Czerw
(38)
,
Ibrahim Yakoub-Agha
(39, 40)
,
Wael Saber
(3)
1
Memorial Sloane Kettering Cancer Center [New York]
2 UCLH - University College London Hospitals NHS Foundation Trust [London, UK]
3 MCW - Medical College of Wisconsin [Milwaukee]
4 UPV - Universitat Politècnica de València = Universitad Politecnica de Valencia = Polytechnic University of Valencia
5 Mayo Clinic
6 Imperial College London
7 Massachusetts General Hospital [Boston]
8 University Hospitals Bristol
9 MUMC - Maastricht University Medical Centre
10 Sarah Cannon Research Institute [Nashville, Tennessee]
11 HIUNJ - Hospital Infantil Universitario Niño Jesús
12 Princess Margaret Hospital
13 City of Hope Comprehensive Cancer Center [Duarte]
14 Mayo Clinic [Rochester]
15 Cleveland State University
16 Jefferson (Philadelphia University + Thomas Jefferson University)
17 Emory University [Atlanta, GA]
18 URMC - University of Rochester Medical Center
19 University of Miami
20 The Ottawa Hospital
21 Vanderbilt University Medical Center [Nashville]
22 Houston Methodist Hospital [Houston, TX, USA]
23 UNIBE - Universität Bern = University of Bern = Université de Berne
24 Penn State Health Milton S. Hershey Medical Center
25 JHU - Johns Hopkins University
26 Dana-Farber Cancer Institute [Boston]
27 KFSHRC - King Faisal Specialist Hospital and Resarch Centre [Riyadh, Saudi Arabia]
28 University of Virginia
29 Mayo Clinic [Jacksonville]
30 UK - University of Kentucky
31 University of Michigan Medical School [Ann Arbor]
32 University of Maryland [Baltimore]
33 Rush University Medical Center [Chicago]
34 H. Lee Moffitt Cancer Center and Research Institute
35 Dokkyo Medical University
36 FHCRC - Fred Hutchinson Cancer Research Center [Seattle]
37 The University of Texas M.D. Anderson Cancer Center [Houston]
38 MCMCC - Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
39 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
40 LIRIC - Lille Inflammation Research International Center - U 995
2 UCLH - University College London Hospitals NHS Foundation Trust [London, UK]
3 MCW - Medical College of Wisconsin [Milwaukee]
4 UPV - Universitat Politècnica de València = Universitad Politecnica de Valencia = Polytechnic University of Valencia
5 Mayo Clinic
6 Imperial College London
7 Massachusetts General Hospital [Boston]
8 University Hospitals Bristol
9 MUMC - Maastricht University Medical Centre
10 Sarah Cannon Research Institute [Nashville, Tennessee]
11 HIUNJ - Hospital Infantil Universitario Niño Jesús
12 Princess Margaret Hospital
13 City of Hope Comprehensive Cancer Center [Duarte]
14 Mayo Clinic [Rochester]
15 Cleveland State University
16 Jefferson (Philadelphia University + Thomas Jefferson University)
17 Emory University [Atlanta, GA]
18 URMC - University of Rochester Medical Center
19 University of Miami
20 The Ottawa Hospital
21 Vanderbilt University Medical Center [Nashville]
22 Houston Methodist Hospital [Houston, TX, USA]
23 UNIBE - Universität Bern = University of Bern = Université de Berne
24 Penn State Health Milton S. Hershey Medical Center
25 JHU - Johns Hopkins University
26 Dana-Farber Cancer Institute [Boston]
27 KFSHRC - King Faisal Specialist Hospital and Resarch Centre [Riyadh, Saudi Arabia]
28 University of Virginia
29 Mayo Clinic [Jacksonville]
30 UK - University of Kentucky
31 University of Michigan Medical School [Ann Arbor]
32 University of Maryland [Baltimore]
33 Rush University Medical Center [Chicago]
34 H. Lee Moffitt Cancer Center and Research Institute
35 Dokkyo Medical University
36 FHCRC - Fred Hutchinson Cancer Research Center [Seattle]
37 The University of Texas M.D. Anderson Cancer Center [Houston]
38 MCMCC - Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
39 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
40 LIRIC - Lille Inflammation Research International Center - U 995
Leo F. Verdonck
- Fonction : Auteur
Jeffrey J. Pu
- Fonction : Auteur
David A. Rizzieri
- Fonction : Auteur
Michael R. Grunwald
- Fonction : Auteur
Résumé
To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the Center for International Blood and Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients who received transplantation in Europe (the European Bone Marrow Transplant [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98-1.96), and HLA-matched unrelated donor (HR, 1.29; 95% CI, 0.98-1.7) were associated with an increased hazard of death and were assigned 1 point. Hemoglobin levels <100 g/L at time of transplantation (HR, 1.63; 95% CI, 1.2-2.19) and a mismatched unrelated donor (HR, 1.78; 95% CI, 1.25-2.52) were assigned 2 points. The 3-year overall survival (OS) in patients with a low (1-2 points), intermediate (3-4 points), and high score (5 points) were 69% (95% CI, 61-76), 51% (95% CI, 46-56.4), and 34% (95% CI, 21-49), respectively (P < .001). Increasing score was predictive of increased transplant-related mortality (TRM; P = .0017) but not of relapse (P = .12). The derived score was predictive of OS (P < .001) and TRM (P = .002) but not of relapse (P = .17) in the EBMT cohort as well. The proposed system was prognostic of survival in 2 large cohorts, CIBMTR and EBMT, and can easily be applied by clinicians consulting patients with MF about the transplantation outcomes.
Domaines
Sciences du Vivant [q-bio]| Origine | Fichiers éditeurs autorisés sur une archive ouverte |
|---|
